LABORATORY RESEARCH AhR Ligand Aminoflavone Inhibits α6-Integrin Expression and Breast Cancer Sphere-Initiating Capacity Scientists investigated the ability of aryl hydrocarbon receptor (AhR) agonist Aminoflavone (AF) and AF pro-drug to disrupt mammospheres derived from breast cancer cells and a M05 mammary mouse model of breast cancer respectively. [Cancer Lett] Abstract Quantification of HER2 Heterogeneity in Breast Cancer-Implications for Identification of Sub-Dominant Clones for Personalized Treatment Using Human Epidermal Growth Factor Receptor 2 (HER2) as an exemplar, researchers developed a simple reproducible heterogeneity index. Cell-to-cell HER2 heterogeneity was extensive in a proportion of both reported ‘amplified’ and ‘non-amplified’ cases. [Sci Rep] Full Article GT198 Expression Defines Mutant Tumor Stroma in Human Breast Cancer Using breast cancer gene product GT198 as a unique marker, researchers revealed the cellular identities of GT198 mutant cells in human breast tumor stroma. GT198 is a steroid hormone receptor coactivator and a crucial factor in DNA repair. [Am J Pathol] Abstract | Press Release Snail-Induced Epithelial-to-Mesenchymal Transition of MCF-7 Breast Cancer Cells: Systems Analysis of Molecular Changes and Their Effect on Radiation and Drug Sensitivity Researchers report the results of a comprehensive systems level molecular analysis of changes in global patterns of gene expression and levels of glutathione and reactive oxygen species in MCF-7 breast cancer cells engineered to constitutively express the zinc-finger transcriptional repressor gene Snail cells and the consequence of these changes on the sensitivity of cells to radiation treatment and therapeutic drugs. [BMC Cancer] Full Article Mammary Tumor Growth and Metastasis Are Reduced in c-Kit Mutant Sash Mice To test the involvement of mast cells in breast cancer, investigators examined the effects of loss of mast cells on mammary tumor development by crossing the well-known mast cell deficient mouse strain sash with the mammary tumor transgenic mouse strain MMTV-Polyoma Middle T antigen. [Cancer Med] Full Article Let-7c Blocks Estrogen-Activated Wnt Signaling in Induction of Self-Renewal of Breast Cancer Stem Cells By analyzing the expression levels of let-7 family members in clinical tissues, investigators found that higher expression levels of let-7b and let-7c were correlated with better clinical prognosis of patients with estrogen receptor α-positive breast tumor. [Cancer Gene Ther] Abstract Selective Cytotoxicity and Modulation of Apoptotic Signature of Breast Cancer Cells by Pithecellobium dulce Leaf Extracts Scientists report the potent and selective cytotoxicity of the crude aqueous leaf extract from the medicinal plant, P. dulce towards the human breast cancer cells (MCF-7), but not the normal cells (MCF-10A). [Biotechnol Prog] Abstract CLINICAL RESEARCH A Non-Randomized Dose-Escalation Phase I Trial of a Protein-Based Immunotherapeutic for the Treatment of Breast Cancer Patients with HER2-Overexpressing Tumors Researchers assessed the safety and immunogenicity of an anti-cancer immunotherapeutic (recombinant HER2 protein combined with the immunostimulant AS15) in patients with early-stage HER2-overexpressing breast cancer. [Breast Cancer Res Treat] Full Article Randomized Phase II Trial of Cyclophosphamide and the Oral Poly (ADP-Ribose) Polymerase Inhibitor Veliparib in Patients with Recurrent, Advanced Triple-Negative Breast Cancer In order to assess the role of poly [ADP-ribose] polymerase (PARP) inhibition in the treatment of triple negative breast cancer (TNBC), investigators conducted a randomized Phase II trial of the combination of veliparib, a small molecule PARP inhibitor, with the cytotoxic agent cyclophosphamide versus cyclophosphamide alone in patients with refractory TNBC. [Invest New Drugs] Full Article |